Why the study?
Resveratrol has known cardiovascular benefits, but its therapeutic effects in pulmonary arterial hypertension have yet to be precisely elucidated.
Does daily oral resveratrol prevent right ventricle remodeling and dysfunction in a rat model of monocrotaline-induced pulmonary arterial hypertension?
Does daily oral resveratrol prevent right ventricle remodeling and dysfunction in a rat model of monocrotaline-induced pulmonary arterial hypertension?
In a rat model of monocrotaline-induced PAH, oral resveratrol prevented right ventricular remodeling and dysfunction at the cardiomyocyte level, suggesting potential as a future adjunct therapy.
No takes yet. Share an insight, caveat, or question.
Resveratrol attenuates experimental PAH; leaves open translation to human disease.
Vázquez‐Garza et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: